findmyKOL

David Zisman, MD

Enriched profile

Care Center Director, Interstitial Lung Disease / Pulmonary Fibrosis Program · Cleveland Clinic Florida

ORCIDNone on fileNPI↗
✓ Full profile
Region🇺🇸 Weston, FL · Southeast · United StatesSpecialtyPulmonary DiseaseFocusIdiopathic Pulmonary Fibrosis
Active KOLEmergingfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

David Zisman is Care Center Director, Interstitial Lung Disease / Pulmonary Fibrosis Program at Cleveland Clinic Florida. ClinicalTrials.gov lists 5 registered studies with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 16 Oct 2026

David A. Zisman, MD, MS, is Care Center Director, Interstitial Lung Disease / Pulmonary Fibrosis Program at Cleveland Clinic Florida (Weston Medical Outpatient Center). The public record shows 76 publications with 6,201 citations (h-index 37), centered on Idiopathic Pulmonary Fibrosis. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 16 companies.

  • Top research focus: Idiopathic Pulmonary Fibrosis
  • 5 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 16 companies

Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Idiopathic Pulmonary Fibrosis5 trialsHypertension3 trialsLung Diseases, Interstitial2 trialsPulmonary Hypertension1 trialPulmonary Arterial Hypertension1 trial

Research focus

OpenAlex concept fingerprint
Idiopathic Pulmonary Fibrosis

Drugs & molecules

across trials, industry payments and publications
Tyvasogeneric · TreprostinilClinical trials—Industry payments56Publications—Ofevgeneric · NintedanibClinical trials—Industry payments15Publications—Olodaterol / tiotropiumClinical trials—Industry payments10Publications—Yupelrigeneric · RevefenacinClinical trials—Industry payments8Publications—Fluticasone Furoate; Umeclidinium Bromide; Vilanterol TrifenatateClinical trials—Industry payments5Publications—Stiolto RespimatClinical trials—Industry payments5Publications—Breztrigeneric · Budesonide / formoterol / glycopyrroniumClinical trials—Industry payments4Publications—Fasenrageneric · BenralizumabClinical trials—Industry payments4Publications—Nucalageneric · MepolizumabClinical trials—Industry payments3Publications—Opsumitgeneric · MacitentanClinical trials—Industry payments3Publications—Perforomistgeneric · FormoterolClinical trials—Industry payments3Publications—Sunosigeneric · SolriamfetolClinical trials—Industry payments3Publications—

Works with

trial sponsors and companies reporting payments
United Therapeutics CorporationClinical trials—Industry payments132Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trials—Industry payments19AstraZeneca Pharmaceuticals LPClinical trials—Industry payments9GlaxoSmithKline, LLC.Clinical trials—Industry payments9Mylan Specialty L.P.Clinical trials—Industry payments7Actelion Pharmaceuticals US, Inc.Clinical trials—Industry payments3Intuitive Surgical, Inc.Clinical trials—Industry payments3Jazz Pharmaceuticals Inc.Clinical trials—Industry payments3Baxter HealthcareClinical trials—Industry payments2Janssen Pharmaceuticals, IncClinical trials—Industry payments2Regeneron Healthcare Solutions, Inc.Clinical trials—Industry payments2Amgen Inc.Clinical trials—Industry payments1Duke UniversityClinical trials1Industry payments—Genentech USA, Inc.Clinical trials—Industry payments1Genentech, Inc.Clinical trials—Industry payments1Genzyme CorporationClinical trials—Industry payments1National Heart, Lung, and Blood Institute (NHLBI)Clinical trials1Industry payments—Rajan SaggarClinical trials1Industry payments—Rein TherapeuticsClinical trials1Industry payments—United TherapeuticsClinical trials1Industry payments—Viatris Specialty LLCClinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
37h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
5clinical trials

Investigator role on registered studies.

View trials ↓
16companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 16 Oct 2026

Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 16 Oct 2026

16 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Respiratory

    53.6%
    Corticosteroid43.8%
    Trelegy Ellipta67%Breo Ellipta14%Breztri Aerosphere10%Fluticasone Propionate6%Symbicort3%
    Part D<11 patients
    beta2-Adrenergic Agonist7.7%
    Albuterol Sulfate Hfa79%Ventolin Hfa21%
    Part D<11 patients

    + 1 more class in this area

  • Cancer & immunology

    20.1%
    Kinase inhibitor15%
    Ofev100%
    Part D≥17 patients
    Calcineurin inhibitor2.8%
    Tacrolimus100%
    Part D<11 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    10.4%
    Corticosteroid8.9%
    Prednisone100%
    Part D≥25 patients
    Proton pump inhibitor1.5%
    Omeprazole100%
    Part D<11 patients
All 9 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)97.7% facility · 2.3% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Online presence

Updated 16 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/david-zisman-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • LinkedIn

    linkedin.com/in/david-zisman-7925185

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗

Mentions by others

where others cite or feature them
  • Other

    pulmonaryfibrosis.org/patients-caregivers/medical-and-support-resources/find-medical-care/care-center-new/cleveland-clinic-florida

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pulmonaryfibrosis.org ↗
  • Doximity

    Doximity profile

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 16 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments

Secondary affiliations

appointments beyond the home institution

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.